Focal therapy - An evolving treatment paradigm for prostate cancer

Timothy Ito, Michael S. Borofsky, Andrew B. Rosenkrantz, Samir S. Taneja

Research output: Contribution to journalArticle

Abstract

Focal therapy for prostate cancer has been proposed as a potential middle ground between active surveillance and radical therapies in patients with clinically localised, low-volume, low-grade disease. Focal therapy with curative intent, aimed at ablating all identified disease, has been agreed upon as an important first step for proof-of-concept. Current consensus also recognises the possibility of use of focal therapy to treat significant disease only while leaving insignificant disease untreated, considerably expanding the number of potential candidates. Transperineal mapping biopsy and multi-parametric magnetic resonance imaging (MRI) currently are the best tools available for mapping disease within the prostate and thus demonstrate the most promise with regards to identifying appropriate candidates for focal therapy. Experience with focal therapeutic modalities, including cryotherapy and high-intensity focused ultrasound (HIFU), has generally been limited to small prospective case series. Preliminary results, however, appear promising, demonstrating good oncological control while limiting morbidity in the form of urinary incontinence and erectile dysfunction. Focal therapy, however, remains experimental at this time, with many challenges to overcome before it can be considered ready for widespread implementation.

Original languageEnglish (US)
Pages (from-to)84-89
Number of pages6
JournalEuropean Urological Review
Volume6
Issue number2
StatePublished - Dec 1 2011

Fingerprint

Prostatic Neoplasms
Therapeutics
Cryotherapy
Urinary Incontinence
Erectile Dysfunction
Prostate
Consensus
Magnetic Resonance Imaging
Morbidity
Biopsy

Keywords

  • Biopsy
  • Cryotherapy
  • Focal therapy
  • High intensity focused ultrasound
  • Index lesion
  • Multi-parametric magnetic resonance imaging
  • Prostate cancer

Cite this

Focal therapy - An evolving treatment paradigm for prostate cancer. / Ito, Timothy; Borofsky, Michael S.; Rosenkrantz, Andrew B.; Taneja, Samir S.

In: European Urological Review, Vol. 6, No. 2, 01.12.2011, p. 84-89.

Research output: Contribution to journalArticle

Ito, T, Borofsky, MS, Rosenkrantz, AB & Taneja, SS 2011, 'Focal therapy - An evolving treatment paradigm for prostate cancer', European Urological Review, vol. 6, no. 2, pp. 84-89.
Ito, Timothy ; Borofsky, Michael S. ; Rosenkrantz, Andrew B. ; Taneja, Samir S. / Focal therapy - An evolving treatment paradigm for prostate cancer. In: European Urological Review. 2011 ; Vol. 6, No. 2. pp. 84-89.
@article{ca29fb52cb0f4e8eb7656a90114b62ca,
title = "Focal therapy - An evolving treatment paradigm for prostate cancer",
abstract = "Focal therapy for prostate cancer has been proposed as a potential middle ground between active surveillance and radical therapies in patients with clinically localised, low-volume, low-grade disease. Focal therapy with curative intent, aimed at ablating all identified disease, has been agreed upon as an important first step for proof-of-concept. Current consensus also recognises the possibility of use of focal therapy to treat significant disease only while leaving insignificant disease untreated, considerably expanding the number of potential candidates. Transperineal mapping biopsy and multi-parametric magnetic resonance imaging (MRI) currently are the best tools available for mapping disease within the prostate and thus demonstrate the most promise with regards to identifying appropriate candidates for focal therapy. Experience with focal therapeutic modalities, including cryotherapy and high-intensity focused ultrasound (HIFU), has generally been limited to small prospective case series. Preliminary results, however, appear promising, demonstrating good oncological control while limiting morbidity in the form of urinary incontinence and erectile dysfunction. Focal therapy, however, remains experimental at this time, with many challenges to overcome before it can be considered ready for widespread implementation.",
keywords = "Biopsy, Cryotherapy, Focal therapy, High intensity focused ultrasound, Index lesion, Multi-parametric magnetic resonance imaging, Prostate cancer",
author = "Timothy Ito and Borofsky, {Michael S.} and Rosenkrantz, {Andrew B.} and Taneja, {Samir S.}",
year = "2011",
month = "12",
day = "1",
language = "English (US)",
volume = "6",
pages = "84--89",
journal = "European Urological Review",
issn = "1758-3829",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - Focal therapy - An evolving treatment paradigm for prostate cancer

AU - Ito, Timothy

AU - Borofsky, Michael S.

AU - Rosenkrantz, Andrew B.

AU - Taneja, Samir S.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Focal therapy for prostate cancer has been proposed as a potential middle ground between active surveillance and radical therapies in patients with clinically localised, low-volume, low-grade disease. Focal therapy with curative intent, aimed at ablating all identified disease, has been agreed upon as an important first step for proof-of-concept. Current consensus also recognises the possibility of use of focal therapy to treat significant disease only while leaving insignificant disease untreated, considerably expanding the number of potential candidates. Transperineal mapping biopsy and multi-parametric magnetic resonance imaging (MRI) currently are the best tools available for mapping disease within the prostate and thus demonstrate the most promise with regards to identifying appropriate candidates for focal therapy. Experience with focal therapeutic modalities, including cryotherapy and high-intensity focused ultrasound (HIFU), has generally been limited to small prospective case series. Preliminary results, however, appear promising, demonstrating good oncological control while limiting morbidity in the form of urinary incontinence and erectile dysfunction. Focal therapy, however, remains experimental at this time, with many challenges to overcome before it can be considered ready for widespread implementation.

AB - Focal therapy for prostate cancer has been proposed as a potential middle ground between active surveillance and radical therapies in patients with clinically localised, low-volume, low-grade disease. Focal therapy with curative intent, aimed at ablating all identified disease, has been agreed upon as an important first step for proof-of-concept. Current consensus also recognises the possibility of use of focal therapy to treat significant disease only while leaving insignificant disease untreated, considerably expanding the number of potential candidates. Transperineal mapping biopsy and multi-parametric magnetic resonance imaging (MRI) currently are the best tools available for mapping disease within the prostate and thus demonstrate the most promise with regards to identifying appropriate candidates for focal therapy. Experience with focal therapeutic modalities, including cryotherapy and high-intensity focused ultrasound (HIFU), has generally been limited to small prospective case series. Preliminary results, however, appear promising, demonstrating good oncological control while limiting morbidity in the form of urinary incontinence and erectile dysfunction. Focal therapy, however, remains experimental at this time, with many challenges to overcome before it can be considered ready for widespread implementation.

KW - Biopsy

KW - Cryotherapy

KW - Focal therapy

KW - High intensity focused ultrasound

KW - Index lesion

KW - Multi-parametric magnetic resonance imaging

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84871824860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871824860&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 84

EP - 89

JO - European Urological Review

JF - European Urological Review

SN - 1758-3829

IS - 2

ER -